首页 > 市场调查报告书 > 製药

DDS

市场调查报告书

商品编码

1140678

全球肠内营养市场-2022-2029

Global Enteral Feeding Formulas Market - 2022-2029

出版日期: 2022年10月20日 | 出版商:

DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

在预测期间（2022-2029 年），肠内营养市场预计将达到 6.8% 的复合年增长率。

肠内餵养是向胃、十二指肠和空肠直接施用含有脂肪、蛋白质、矿物质、碳水化合物、水和维生素的营养完整的饮食。用于输送肠内营养的管有多种类型，包括胃造口术、鼻空肠管、鼻胃管和空肠瘘管。这些管子由硅胶、聚氨酯或 PVC 製成，长度从 30 到 43 英寸不等，成人的直径从 8 到 14 英寸不等。用于肠内餵养的其他设备包括剂量容器（瓶子、饲料袋等）、注射器和肠内泵。各种途径用于管理必要的营养素，但可以选择具有成本效益、健康和侵入性的过程。因进食障碍（如神经性厌食、吞嚥困难和胃炎）而导致营养不良的患者首选肠内营养。

市场动态

肠内营养的需求猛增，加上肠内营养治疗用途的增加和新技术先进肠内营养的引入。此外，全球人口老龄化和早产率上升也在推动市场增长。

慢性病的高患病率推动市场增长

心血管疾病、癌症、糖尿病和（冠状动脉阻塞性肺病）慢性阻塞性肺病等慢性病患病率的增加预计将推动肠内营养市场的增长。

根据国际糖尿病联盟的数据，2021 年糖尿病患者将花费 9660 亿美元的医疗保健费用，其中 9% 将用于成人。目前，约有 5.37 亿成年人（20-79 岁）患有糖尿病，预计到 2045 年将增加到 7.83 亿。在大多数国家，2 型糖尿病患者的比例正在增加。大约 5.41 亿成年人患 2 型糖尿病的风险增加。据估计，到 2035 年，这种流行率将增加到 45%。根据美国疾病控制和预防中心 (CDC) 的数据，大约一半 (47%) 的美国人口至少有这三个风险因素之一。

治疗这些慢性疾病需要更长的住院时间和恢復期。她也有吞嚥食物的问题，所以她通过管子从外部餵食。因此，预计癌症和心血管疾病等慢性疾病的患病率将在预测期内推动市场增长。

医疗报销不足阻碍肠内营养市场增长

预计肠内营养报销不足将阻碍肠内营养的使用，并降低预测期内肠内营养的采用率。

市场细分。

全球肠内营养市场根据产品、流程类型、阶段、应用和最终用户进行细分。

肿瘤学有望在肠内营养市场占据较大市场份额

全世界的癌症负担正在迅速增加。预计癌症将在预测期内迅速增长。世界卫生组织报告称，癌症是全球第二大死因，2020 年全球造成 1000 万人死亡，即六分之一的死亡。大约 70% 的癌症死亡发生在低收入和中等收入国家。据世界卫生组织统计，每年约有 1790 万人死于心血管疾病，占全球死亡人数的 32%。大多数患有癌症的患者患有癌症恶病质，这会导致胰岛素抵抗、脂肪分解增加、体脂减少、蛋白质周转增加、肌肉质量下降、食慾下降和体重下降。

此外，接受癌症治疗的患者还会因唾液量的变化而出现咀嚼和吞嚥固体食物困难、口腔粘膜炎、吞嚥困难等并发症和副作用。为了改善此类患者的临床状况，对经口摄入困难的癌症患者进行肠内营养管餵养，以帮助他们保持体质。

在预测期内，标准製剂市场预计将占最大份额

按产品分为标准产品和针对疾病的配方。其中，由于对肠内营养和基础临床营养的高需求、商业可用性以及大公司不断增加的投资，标准产品细分市场份额最大。标准配方领域进一步分为聚合物配方和单体配方。随着对低成本营养补充剂的需求不断增长，市场上出现了各种各样的标准化配方。对容量敏感的患者以及患有充血性心力衰竭、SIADH（利尿激素不适当综合征）和肾衰竭的患者对标准管饲的需求更高。

同时，由于肠内营养和设备的改进以及几种慢性病患病率的上升，在 2020-2027 年的预测期内，针对特定疾病的处方将增长最快。特定疾病配方领域进一步细分为肾臟、糖尿病、肝臟、肺和其他。医疗保健专业人员和患者对肠内营养益处的认识不断提高是推动这一细分市场增长的关键因素之一。

分阶段来看，2019年成人细分市场份额最大

根据阶段，市场分为成人和儿童。由于成年人越来越多地采用管饲法，成人部分在 2019 年占据了最大的市场份额。对于成人，可以通过注射器法、重力滴注法或泵法进行肠内餵养。Medical Nutrition International Industry 的一项研究表明，欧盟与营养不良或营养不良相关的财务成本约为 1850 亿美元。世界上约有六分之一的人受到营养不良的影响。成年人对营养配方奶粉的需求不断增长是推动该细分市场增长的主要因素之一。

另一方面，由于早产儿增加和住院儿童营养不良患病率上升，预计儿科部门在预测期内将显着增长。例如，根据联合国儿童基金会、世界卫生组织和世界银行发布的一份报告，到 2020 年，超过五分之一的儿童，即约 1.492 亿儿童将发育迟缓。胃肠功能障碍的儿科患者因为不能口服营养，所以必须给予肠内营养。一些患有严重胃食管反流、过敏、食物排斥行为和代谢紊乱等胃肠道疾病的儿科患者也采用管饲法。

从最终用户来看，家庭护理预计在预测期内将显着增长。

由于营养平衡意识的提高和接受家庭肠内营养的患者人数增加，家庭医疗保健预计将在预测期内以最快的速度增长。家庭保健患者中肠内营养的采用正在增加。与国家临床卓越研究所 (NICE) 合作制定的政策，旨在彻底改变医疗保健服务并加强为使用营养补充剂的患者提供的服务。

按地理

北美在全球肠内营养市场占有最大份额

由于老年人口不断增加、早产患病率上升、慢性病患病率上升等因素，北美地区将在 2021 年占据全球肠内营养市场的最大市场份额。美国是肠内营养市场增长的主要贡献者。到 2060 年，美国 65 岁及以上的人口数量预计将增加一倍以上。预计人口老龄化将增加癌症和糖尿病等慢性病的数量，导致患者住院时间延长。据世界卫生组织称，大约有 1500 万婴儿早产，而且这个数字还在上升。因此，预计在预测期内，该地区的市场将进一步增长。

亚太地区在预测期内以最快的复合年增长率增长。

预计亚太市场在预测期内将以最快的复合年增长率增长。日本、中国和印度的市场是由大量慢性病和残疾患者、早产增加、医疗成本上升、医疗基础设施的快速发展以及这些国家的需求增加所驱动的。预计在预测期内将显着增长。

竞争格局。

肠内营养市场是一个竞争激烈的市场，既有国内的，也有全球的。为市场增长做出贡献的主要公司包括 Abbott Laboratories、Fresenius Kabi AG、B. Braun Melsungen AG 和 Steelcase。Braun Melsungen AG、Victus, Inc、Hormel Food Corp、Danone SA、Nestle SA、Mead Johnson Nutrition Company、Global Health Products, Inc、Meiji Holdings Co., Ltd.、Trovita Health Science 等。

B. Braun Melsungen AG

概述

B. Brown 主要在医疗技术、医疗服务和製药领域製造、营销和分销一系列医疗保健产品和服务。该公司的产品阵容涵盖大约 5,000 种产品，其中 95% 是内部製造的。主要产品包括用于输液、营养和疼痛治疗的一次性用品、输液泵和系统、手术器械、缝合材料、髋关节和膝关节植入物、透析设备和配件、造口和伤口护理产品。B.Brown 在 64 个国家/地区开展业务，并在医疗保健行业的 18 个治疗领域开发产品。它通过五个业务部门运营：医院护理、Aesculap、B. Braun Avitum、门诊市场 (OPM) 和其他销售部门。

产品介绍

肠内营养泵

Enteroport(R) plus：肠内营养泵

用于肠内营养泵“Enterport(R) Plus”的附件 Enterport(R) Plus

饲管

Nutritab(R)：聚氨酯进料管

胃造口管。用于鼻胃管和鼻肠管的 PVC 管，仅供短期使用。

十二指肠管。pvc管

其他

重大发展

领先企业正在采取多种增长战略，例如产品发布、收购和合作伙伴关係，这有助于全球肠内营养市场的增长。例如：

2020 年 6 月，Hormel Foods被 3BL Media 评为“100 家最佳企业公民”之一，表彰其在美国 1000 家最大的上市公司中出色的环境、社会和治理 (ESG) 透明度和业绩增长。这增加了公司的信誉并在市场上建立了知名度

2022 年 4 月 29 日，Fresenius Kabi推出了一款新的肠内营养产品应用程序。该应用程序适用于英国和爱尔兰共和国的医护人员。

COVID-19 影响分析

随着医院中 COVID-19 病例的增加，对肠内配方的需求也在增加。2020 年，由于 COVID-19 患者的增加，肠内营养行业在重症监护领域出现了繁荣，导致通气患者的营养补充剂消费量增加。

提高医护人员对医院相关营养不良的认识预计将增加医院肠内营养的使用。此外，在 COVID-19 期间 ICU 入院人数增加，危重患者对肠内营养的需求增加可能会推动市场增长。

Market Overview

Enteral Feeding Formulas Market is expected to reach at a CAGR of 6.8% during the forecast period (2022-2029).

Enteral feeding is the delivery of a nutritionally complete feed containing fat, protein, minerals, carbohydrate, water, and vitamins, directly to the stomach, duodenum, or jejunum. There are various types of tubes available for enteral feed formulae, such as gastrostomy, nasojejunal tube, nasogastric tube, and jejunostomy. These tubes are made of silicone, polyurethane, or PVC and are of different lengths from 30 to 43 inches, with diameters from 8 to 14 inches for adults. Some of the other equipment used for enteral feeding include an administration reservoir (bottle, feed bag, etc.), syringes, and enteral pump. Various routes are used in the administration of the necessary nutrients are cost-effective, healthy, and also a choice for the invasive process. Enteral feeding is preferred for patients with malnutrition due to eating disorders such as anorexia nervosa, dysphagia, and stomach infections, among others.

Market Dynamics

The demand for enteral feeding formula demand is surging with rising therapeutic uses of enteral feeding formula coupled with the introduction of new technologically advanced enteral feeding formula. In addition, the growing geriatric population globally and the rising prevalence of preterm births are also boosting the market growth.

The high prevalence rate of chronic disorders is driving the market growth

Increasing incidences of chronic disorders, such as cardiovascular diseases, cancer, diabetes, and (Coronary Obstructive Pulmonary Disorders) COPD are expected to drive the growth of the enteral feeding formulas market.

As per the International Diabetes Federation, diabetes patients spent US$ 966 billion in health expenditure in 2021, of which, 9 percent of total spending on adults. Around 537 million adults (20-79 years) are living with diabetes currently, and by 2045 this is projected to rise to 783 million. The proportion of type 2 diabetes people is increasing in most countries. Around 541 million adults' people are at increased risk of developing type 2 diabetes. population was suffering from some form of cardiac disease; it is further estimated that this prevalence is likely to increase to 45% by 2035. According to the Centers for Disease Control and Prevention (CDC) of the U.S., about half of the population (47%) of the United States have at least one of these three risk factors.

For the treatment of these chronic diseases, a longer hospital stays and recovery time is required. Patients face problems in swallowing food, so, external nutrition is given to the patient through the tube. Hence, the increase in the cases of chronic diseases, such as cancer and cardiovascular diseases, is expected to drive the growth of the market over the forecast period.

Lack of reimbursement is hampering the growth of the enteral feeding formulas market

The lack of reimbursement of enteral feeding formula is expected to hamper the usage of enteral feeding formula and lower the adoption rate of the enteral feeding formula in the forecast period.

Market Segmentation:

The global enteral feeding formulas market is segmented based on product, flow type, stage, application, and end-users.

The oncology segment is expected to hold a major market share in the enteral feeding formulas market

The burden of cancer is growing rapidly worldwide. Cancer is expected to grow rapidly during the forecast period. The WHO has reported that cancer is the second leading cause of death globally and is responsible for 10 million deaths or one death in 6 deaths in 2020 and worldwide. Also, around 70% of deaths from cancer occur in low and middle-income countries. WHO stated that around 17.9 million people die every year with cardiovascular diseases, and globally, it accounts for 32% of deaths. The majority of tumor-bearing patients suffer from cancer cachexia, which causes insulin resistance, increased lipolysis with loss of body fat, increased protein turnover, and loss of muscle mass, causing loss of appetite and weight.

Also, there are several complications and side effects in the patients while cancer treatment, including difficulty in chewing and swallowing solid food, mucositis sores in the mouth, altered saliva level, which makes it difficult to swallow. To improve the clinical condition of patients, delivery of nutrition is very difficult for the cancer patients to take the food orally, hence, the nutrition is supplied by enteral feeding tubes to help them maintain the body mass.

The standard formulas segment is expected to hold the largest market share during the forecast period

By product, the market is classified into standard and disease-specific formulas. Among these, the standard formulas segment accounted for the largest market share due to its high demand for enteral nutrition and basic clinical nutrition, high commercial availability, and growing investment by major companies. The standard formulas segment is further segmented into polymeric formulas and monomeric formulas. There are different varieties of standard formulas available with the growing demand for low-cost nutrient formulations. The demand for standard tube feeds is high among volume-sensitive patients or patients with congestive heart failure, Syndrome of Inappropriate Diuretic Hormone (SIADH), and renal failure.

On the other hand, the disease-specific formulas are expected to grow at the fastest growth rate during the forecast period, 2020 to 2027 due to growing improvements in enteral feeding formula and devices with the rising prevalence of several chronic diseases. The disease-specific formulas segment is further segmented into renal, diabetic, hepatic, pulmonary, and others. Growing awareness among healthcare professionals and the patient population towards the benefits of enteral medical foods is one of the major factors driving the segment growth.

By Stage, the Adult Segment held the largest market share in 2019

Based on stage, the market is segmented into adults and pediatrics. The adult segment accounted for the largest market share in 2019, due to the growing adoption of tube feed among adults. The enteral feeding can be performed by the syringe method, gravity drip method, and pump method in adults. According to a study by the Medical Nutrition International Industry, the financial cost associated with malnutrition or undernutrition in the European Union is around US$ 185 billion. About one in six individuals are affected by malnutrition globally. The growing demand for such nutrition formulations in the adult population is one of the major factors boosting segment growth.

On the other hand, the pediatrics segment is expected to grow significantly over the forecast period, due to the rising number of premature births and increasing prevalence rate of malnutrition among hospitalized children. For instance, as per the report published by UNICEF-WHO-World Bank, more than one in five that is around 149.2 million children were stunted in 2020. Pediatric patients with a dysfunctional gastrointestinal tract cannot ingest nutrients orally and thus administer enteral feeding. Some pediatric patients suffering from gastrointestinal disorders, such as severe gastroesophageal reflux, allergies, food refusal behavior, and metabolic disorders are also provided tube feeding.

By End-user, Home care is expected to grow significantly over the forecast period.

Home care is expected to grow at the fastest growth rate over the forecast period, owing to the rising number of patients receiving home enteral feeding with growing awareness towards balanced nutrition. There is a rise in the adoption of enteral feeding formulas among home healthcare patients. A policy was developed in combination with the National Institute for Clinical Excellence (NICE) which has revolutionized the healthcare service for patients on nutrition supplements and has enhanced the service delivery. Geographical Presentation:

North America region holds the largest market share in the global enteral feeding formulas market

North America region is dominating the global enteral feeding formulas market accounted for the largest market share in 2021, due to several factors, such as the growing geriatric population, rising prevalence of preterm birth, and the increasing number of chronic disease patients. The United States is the major contributor to the growth of the enteral feeding formulas market. In the U.S., it is projected that the number of people aged above 65 years will more than double by 2060. The growing geriatric population would increase the cases of chronic diseases, such as cancer and diabetes, which will lead to an increase in the hospital stay of the patient. Also, according to the WHO, around 15 million babies are born preterm, and this number is rising. Hence, the market is expected to grow further in this region over the forecast period.

Asia-Pacific region is growing at the fastest CAGR during the forecast period.

The Asia Pacific market is expected to grow at the fastest CAGR during the forecast period. The market in Japan, China, and India is likely to grow significantly during the forecast period, due to the large presence of patients suffering from chronic diseases and disorders, increasing incidences of preterm births, growing healthcare expenditure, rapidly developing healthcare infrastructure, and growing demand in these countries.

Competitive Landscape:

The enteral feeding formulas market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Fresenius Kabi AG, B. Braun Melsungen AG, Victus, Inc., Hormel Food Corp., Danone S.A., Nestle S.A., Mead Johnson Nutrition Company, Global Health Products, Inc., Meiji Holdings Co., Ltd., Trovita Health Science, among others.

B. Braun Melsungen AG

Overview:

B. Braun is majorly involved in the manufacturing, marketing, and distributing of various healthcare products and services in the fields of medical technology, medical services, and pharmaceutical products. The company's product range comprises around 5,000 products of which 95% of the products are manufactured by the company. Some of the major product lines manufactured by the company include disposables required for infusion, nutrition and pain therapy, infusion pumps and systems, surgical instruments, suture materials, hip and knee implants, dialysis equipment and accessories, and stoma and wound care products. B. Braun has a presence in 64 countries and develops products in 18 therapy fields of the healthcare industry. The company operates its business through five business divisions which include hospital care, Aesculap, B. Braun Avitum, out-patient market (OPM), and other sales.

Product Portfolio:

Enteral Nutrition Pumps:

Enteroport® plus: Enteral nutrition pump

Accessories Enteroport® plus: Accessories for the enteral nutrition pump Enterport® plus

Feeding Tubes

Nutritub®: Polyurethane feeding tube

Gastric Tubes: Nasogastric and naso-intestinal PVC tubes for short-term use only.

Duodenal Tubes: PVC tube

Others

Key Development:

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Enteral Feeding Formulas market globally. For instance,

In June 2020, Hormel Foods has been named to the 100 Best Corporate Citizens list by 3BL Media, recognizing outstanding environmental, social, and governance (ESG) transparency and performance among the 1,000 largest U.S. public companies. This increases the credibility of the company and establishes a good name in the market

On 29th April 2022, Fresenius Kabi launched its new Enteral nutrition product app. That app is available for healthcare professionals in the United Kingdom and the Republic of Ireland.

COVID-19 Impact Analysis

The demand for enteral feeding formulas is growing with the increasing number of COVID-19 cases in hospitals. In 2020, the critical care segment is rapidly growing in the enteral feeding formula industry due to the rising number of COVID-19 patients, which are also leading to the consumption of nutritional feeding formulas more towards the patients with ventilators.

Growing awareness among healthcare professionals regarding hospital-associated malnutrition is anticipated to boost the usage rate of enteral feeding formulas in hospitals. Moreover, the increasing number of ICU admissions during COVID-19, rising demand for enteral formulations among critically ill patients, are likely to boost the market growth.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet by Product
3.2. Market Snippet by Stage
3.3. Market Snippet by Flow Type
3.4. Market Snippet by Application
3.5. Market Snippet by End-User
3.6. Market Snippet by Region

4. Market Dynamics

4.1. Market Impacting Factors
4.2. Drivers
- 4.2.1. Rising prevalence of chronic diseases and disorders
- 4.2.2. Growing number of preterm births
- 4.2.3. Technological advancement in feeding formulas
- 4.2.4. XX
4.3. Restraints
- 4.3.1. Complications associated with enteral feeding
- 4.3.2. XX
4.4. Opportunity
4.5. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Unmet Needs

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
- 7.1.2. Market Attractiveness Index, By Product Segment
7.2. Disease-specific Formulas*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 7.2.3. Pulmonary Formulas
- 7.2.4. Diabetic Formulas
- 7.2.5. Hepatic Formulas
- 7.2.6. Renal Formulas
- 7.2.7. Others
7.3. Standard Formulas
- 7.3.1. Monomeric Formulas
- 7.3.2. Polymeric Formulas

8. By Stage

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
- 8.1.2. Market Attractiveness Index, By Stage Segment
8.2. Adults *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.3. Pediatrics

9. By Flow Type

9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
- 9.1.2. Market Attractiveness Index, By Flow Type Segment
9.2. Intermittent Feeding Flow*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
9.3. Continuous Feeding Flow

10. By Application

10.1. Introduction
- 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
- 10.1.2. Market Attractiveness Index, By Application Segment
10.2. Oncology*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
10.3. Diabetes
10.4. Neurology
10.5. Gastroenterology
10.6. Critical Care
10.7. Others

11. By End-User

11.1. Introduction
- 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
- 11.1.2. Market Attractiveness Index, By End-User Segment
11.2. Hospitals*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
11.3. Homecare Agencies & Hospices
11.4. Long-term Care Facilities
11.5. Nursing Homes
11.6. Others

12. By Region

12.1. Introduction
12.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
12.3. Market Attractiveness Index, By Region
12.4. North America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
- 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
- 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
- 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.4.8.1. U.S.
  - 12.4.8.2. Canada
  - 12.4.8.3. Mexico
12.5. Europe
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
- 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
- 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
- 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.5.8.1. Germany
  - 12.5.8.2. U.K.
  - 12.5.8.3. France
  - 12.5.8.4. Italy
  - 12.5.8.5. Spain
  - 12.5.8.6. Rest of Europe
12.6. South America
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
- 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
- 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
- 12.6.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.6.8.1. Brazil
  - 12.6.8.2. Argentina
  - 12.6.8.3. Rest of South America
12.7. Asia Pacific
- 12.7.1. Introduction
- 12.7.2. Key Region-Specific Dynamics
- 12.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 12.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
- 12.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
- 12.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
- 12.7.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.7.8.1. China
  - 12.7.8.2. India
  - 12.7.8.3. Japan
  - 12.7.8.4. Australia
  - 12.7.8.5. Rest of Asia Pacific
12.8. Middle East and Africa
- 12.8.1. Introduction
- 12.8.2. Key Region-Specific Dynamics
- 12.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 12.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
- 12.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
- 12.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.8.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

13. Competitive Landscape

13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis

14. Company Profiles

14.1. Abbott Laboratories*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Key Highlights
- 14.1.4. Financial Overview
14.2. Fresenius Kabi AG
14.3. B. Braun Melsungen AG
14.4. Victus, Inc.
14.5. Danone S.A.
14.6. Nestle S.A.
14.7. Mead Johnson Nutrition Company
14.8. Health Products, Inc.
14.9. Meiji Holdings Co., Ltd.,
14.10. Trovita Health Science (List Not Exhaustive)

15. DataM Intelligence

15.1. Appendix
15.2. About Us and Services
15.3. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

全球肠内营养市场-2022-2029

Global Enteral Feeding Formulas Market - 2022-2029

市场概况

市场动态

市场细分。

按地理

竞争格局。

概述

产品介绍

肠内营养泵

重大发展

COVID-19 影响分析

目录

第一章 调查方法和范围

第二章市场定义和概述

第三章执行摘要

第四章市场动态

第五章行业分析

第 6 章 COVID-19 分析

第 7 章按产品分类

第8章 分阶段

第 9 章 按流程类型

第 10 章 按应用

第 11 章最终用户

第12章按地区

第十三章 竞争格局

第十四章公司简介

第 15 章 数据管理